First-Line Treatment Options for HER2+ Metastatic Colorectal Cancer

Video

Dr Bekaii-Saab provides an overview of the first-line treatment options in metastatic colorectal cancer, and the factors that impact treatment decision-making.

OND0539_CRC_ATP_Seg06_OPTIONS
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
      Novel Treatments May Have the Potential to Impact GI Cancer Care
      Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
      CRC Yields Most Prevalent Data at Recent GI Meeting
      4 experts in this video
      Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
      4 experts in this video
      Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
      Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
      PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Mets
      Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
      Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
      Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
      Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
      5 experts in this video
      CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
      4 experts in this video
      PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
      5 experts in this video
      Transplant-Eligible, CAR T Considered: How Do We Decide?
      Related Content
      HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

      HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

      Tim Cortese
      March 31st 2025
      Article

      Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

      Marwan G. Fakih, MD
      February 24th 2025
      Podcast

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

      Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer

      Russ Conroy
      March 31st 2025
      Article

      Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

      Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

      Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

      Jagoda Misniakiewicz, PharmD
      June 10th 2024
      Podcast

      Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

      In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.

      Suvemcitug Combination Therapy Exhibits Safety, Activity in MSS/pMMR CRC

      Roman Fabbricatore
      March 2nd 2025
      Article

      In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.

      Phase 3 CheckMate-8HW trial results evaluating the combination in microsatellite instability–high or mismatch repair deficient CRC supported the decision.

      FDA Grants Priority Review to Nivolumab/Ipilimumab in MSI-H/dMMR CRC

      Roman Fabbricatore
      February 24th 2025
      Article

      Phase 3 CheckMate-8HW trial results evaluating the combination in microsatellite instability–high or mismatch repair deficient CRC supported the decision.